Clinical Significance of Epigenetic Inactivation of hMLH1 and BRCA1 in Tunisian Patients with Invasive Breast Carcinoma
Table 2
Association between gene promoter methylation and clinicopathological features ER and p53 expression in breast cancer.
BRCA1
hMLH1
M (%)
U (%)
M (%)
U (%)
N
78
35 (44.8)
43 (55.1)
17 (21.7)
57 (73)
Age
45
30
19 (63.3)
11 (36.7)
6 (21.4)
22 (78.6)
45
48
16 (33.3)
32 (66.7)
11 (23.9)
35 (76.1)
.01
.8
Tumor size
mm
38
18 (47.4)
20 (52.6)
3 (8.1)
34 (91.9)
mm
40
17 (42.5)
23 (57.5)
14 (37.8)
23 (62.2)
.66
.002
(a)Metastasis
No
37
18 (48.6)
19 (51.4)
1 (2.8)
35 (97.2)
Yes
14
8 (37.1)
6 (42.9)
4 (30.8)
9 (69.2)
.58
.004
(a)DFS
5 years
22
7 (31.8)
15 (68.2)
3 (14.3)
18 (87.5)
5 years
12
9 (75)
3 (25)
1 (8.3)
11 (91.7)
.015
.6
(a)Response to radiotherapy
Radiosensitive
37
18 (48.6)
19 (51.4)
1 (2.8)
35 (97.2)
Radioresistant
14
8 (57.1)
6 (42.9)
4 (30.8)
9 (69.2)
.58
.004
ER
Positive
19
9 (47.4)
10 (52.6)
7 (36.8)
12 (63.2)
Moderate
28
11 (39.3)
17 (60.7)
2 (7.7)
24 (92.3)
Negative
31
15 (48.4)
16 (51.6)
8 (27.6)
21 (72.4)
.75
.054
(a)P53
Positive
16
9 (56.3)
7 (43.8)
Negative
23
10 (43.5)
13 (56.5)
5 (68.8)
11 (31.3)
0 (0)
21 (100)
.44
.006
DFS: Disease Free Survival, ER: Estrogen Receptor. Data for DFS, response to radiotherapy, metastasis, and p53 status were not available for all specimens. Comparisons of DFS and P53 status was made by Fisher’s exact test and all other comparisons were by the 2 test.
